Correction to: Acta Pharmacologica Sinica (2024) 45:1276-1286 https://doi.org/10.1038/s41401-024-01243-6; Article published online 4 March 2024

Substituents of active compounds FKB04 are incorrectly plotted in Figure 2a and supporting information.The correct version including the structure and scheme of FKB04 is shown. The corrigendum does not affect the interpretation of data and conclusions, The authors deeply feel sorry and apologize for all the inconvenience this may have caused.

Corrected

a The FKB04 chemical structure. b Liver cancer cells and liver normal cell lines were pretreated with FKB04 for 2 days, and the IC50 was calculated according to the MTT assay. c Detection of TRF2 expression in liver cancer cells and liver cells by Western blot assay. d Cell proliferation curves of Huh-7 and HepG2 in FKB04-treated cells and normal controls at indicated doses (1.0, 2.0, and 4.0 μM). e Colony formation assay in liver cancer cells treated with 1.0, 2.0, and 4.0 μM FKB04 for 10 days. f Transwell assay was used to measure the effect of FKB04 on the migration of liver cancer cells (200×). g β-Galactosidase staining method to detect senescence phenotype among cells pretreated with FKB04 (1.0, 2.0, and 4.0 μM) for 7 days. β-Galactosidase staining of 200 or more cells was quantified for each group (200×). h Quantification of g. i Western blot assays of p53, p-p53, p16, Lamin B1, and p21 protein expression levels in FKB04-treated Huh-7/HepG2 cells and normal controls at indicated doses (1.0, 2.0, and 4.0 μM) for 7 days. GAPDH was set as an internal loading control. An unpaired Student’s two-tailed t-test was performed to determine the statistical significance. ns indicates no significant -difference, *P < 0.05, **P < 0.01, ***P < 0.001.

Corrected scheme:

We used 2′-Hydroxy-4′,6′-dimethoxyacetophenone, and corresponding benzaldehyde to obtain Flavokavain B and FKB04.

The original article has been corrected.